On Thursday, Insys Therapeutics Inc(NASDAQ:INSY)’s shares declined -4.59% to $32.67.
Insys Therapeutics Inc (INSY) declared it has filed a Citizen Petition with the Drug Enforcement Administration (“DEA”) to request the agency replan its synthetic pharmaceutical cannabidiol (“CBD”) from Plan I to Plan IV. The Company believes that the current classification of synthetic CBD as a Plan I compound is a noteworthybarrier to the progress of research studies that explore the value of this compound in the treatment of several serious medical conditions. Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also comprise Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol.
A10 Netoperates Inc(NYSE:ATEN)’s shares dropped -5.66% to $6.67.
A10 Networks, Inc. (ATEN), a technology leader in application networking, recently declared financial results for its second quarter ended June 30, 2015.
Total revenue for the second quarter grew to $47.5 million, contrast with $45.1 million in the second quarter of 2014. On a GAAP basis, A10 Networks stated a net loss for the second quarter 2015 of $10.0 million or $0.16 per share, contrast with a net loss of $1.3 million or $0.02 per share in the second quarter of 2014. Non-GAAP net loss for the second quarter of 2015 was $5.3 million or $0.09 per share, contrast with a non-GAAP net loss of $5.3 million or $0.09 per share in the second quarter of 2014.
Recent Highlights
- Released a centralized administration system for the Thunder ADC and Thunder TPS platforms. aGalaxy leverages the fully programmable policy engine in ACOS to provide strong configuration administration, reporting, and real-time traffic analysis.
- KDDI Corporation has selected A10’s virtual ADC, the A10 vThunder ADC, as its preferred application delivery controller for its corporate cloud infrastructure, KDDI Cloud Platform Service (KCPS). KCPS subscribers can now benefit from vThunder ADC features, counting server load balancing, DDoS protection and high density multi-tenancy.
- Added the vThunder ADC to the Microsoft Azure Marketplace, allowing Azure customers to integrate private and public cloud services with the full feature set of an advanced ADC for the first time.
A10 Networks, Inc. provides software based application networking solutions in the United States, Japan, and internationally. Its solutions are built on advanced core operating system platform. The company provides application delivery controllers for optimizing data center performance; carrier grade networking products that offer address and protocol translation services for service provider networks; and a distributed denial of service threat protection system for network-wide security protection.
At the end of Thursday’s trade, Nordic American Tanker Ltd(NYSE:NAT)‘s shares dipped -4.23% to $13.81.
NAO is a start-up company that became listed on the New York Stock Exchange (NYSE) on June 12, 2014. Our ship administration partners, board and staff have a wealth of experience in the offshore and Platform Supply Vessel (PSV) business, with some involved as early as from the 1980s. NAO is well positioned to capitalize on the challenging market conditions in the offshore sector which may represent a commercial opportunity for NAO. The result for 2Q2015 is better than 1Q2015. Counting the recently agreed credit facility of $150m, NAO is fully financed up to early 2020.
The dividend policy of NAO is a fundamental element of our strategy.
As declared on July 21, 2015, NAO has declared a dividend of $0.17 per share for 2Q2015. The record date is August 5, 2015 and the payment of dividend is predictable to take place about August 19, 2015. Since its inception in late 2013, NAO has paid dividends for 6 successive quarters, totalling $2.14 per share, counting the dividend to be paid about August 19, 2015. In June 2014, NAO relocated from the Oslo OTC (Over the Counter) exchange to the New York Stock Exchange (NYSE).
Nordic American Tankers Limited, a tanker company, engages in acquiring and chartering double-hull tankers. As of December 31, 2014, it owned 24 Suezmax crude oil tankers, counting two new buildings under construction. The company was founded in 1995 and is based in Hamilton, Bermuda.
Allergan PLC(NYSE:AGN), ended its Thursday’s trading session with -3.37% loss, and closed at $308.11.
Allergan plc (AGN) stated continued exceptional performance with net revenue increasing 116 percent to $5.76 billion for the quarter ended June 30, 2015, contrast to $2.67 billion in the second quarter 2014. On a non-GAAP basis, diluted earnings per share raised 29 percent to $4.41 for the second quarter 2015, contrast to $3.42 in the second quarter 2014. GAAP loss per share for the second quarter 2015 was $0.80, contrast to GAAP income per diluted share of $0.28 in the preceding year period. GAAP results were influenced by amortization, in-process research and development impairments, acquisition-related expenses, acquisition accounting valuation related expenses and severance and integration costs associated with attained businesses, mainly the acquisitions of Allergan on March 17, 2015 and Forest Laboratories on July 1, 2014.
Other Operating Results
For the second quarter 2015, non-GAAP gross margin was 72.3 percent contrast to 56.3 percent in the second quarter of 2014, reflecting the impact of the Allergan acquisition. Total non-GAAP SG&A as a percent of non-GAAP revenue for the second quarter 2015 was 21.7% contrast to 18.7% in the preceding year period. For the second quarter 2015, non-GAAP R&D spending was $406.0 million contrast to $184.8 million in the preceding year. Adjusted EBITDA raised 203 percent to $2.61 billion in the second quarter of 2015, contrast to $862.0 million for the second quarter 2014. Cash flow from operations for the second quarter of 2015 was $1.4 billion and cash and marketable securities were $1.5 billion as of June 30, 2015.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
